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Background: The purpose of this study was to develop a prognostic model for the survival of pediatric patients
with rhabdomyosarcoma (RMS) using parameters that are measured during routine clinical management.
Methods: Demographic and clinical variables were evaluated in 1679 pediatric patients with RMS registered in the
Surveillance, Epidemiology, and End Results (SEER) program from 1990 to 2010. A multivariate Cox proportional
hazards model was developed to predict median, 5-year and 10-year overall survival (OS). The Akaike information
criterion technique was used for model selection. A nomogram was constructed using the reduced model after
model selection, and was internally validated.
Results: Of the total 1679 patients, 543 died. The 5-year OS rate was 64.5% (95% confidence interval (CI), 62.1-67.1%)
and the 10-year OS was 61.8% (95%CI, 59.2-64.5%) for the entire cohort. Multivariate analysis identified age at diagnosis,
tumor size, histological type, tumor stage, surgery and radiotherapy as significantly associated with survival (p < 0.05).
The bootstrap-corrected c-index for the model was 0.74. The calibration curve suggested that the model was well
calibrated for all predictions.
Conclusions: This study provided an objective analysis of all currently available data for pediatric RMS from the
SEER cancer registry. A nomogram based on parameters that are measured on a routine basis was developed. The
nomogram can be used to predict 5- and 10-year OS with reasonable accuracy. This information will be useful for
estimating prognosis and in guiding treatment selection.
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Rhabdomyosarcoma (RMS) is the most common soft-
tissue sarcoma in children and adolescents and accounts
for 3% of all pediatric tumors [1]. Approximately 350
children are diagnosed with RMS in the United States
every year [2]. Incidence peaks at a very young age. Be-
cause RMS is derived from immature striated skeletal
muscle, this disease can occur at any site in the body.
Prognosis of RMS has improved significantly, with
multidisciplinary management accounting for most of
the increase in survival rate. Since 1972, the Intergroup
Rhabdomyosarcoma Study Group (IRSG) has conducted* Correspondence: yo-r@ncchd.go.jp
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unless otherwise stated.a series of clinical trials and published a series of treat-
ment guidelines for different primary sites. As a result,
the long-term survival rate of these patients has nearly
tripled from approximately 25% in 1970 to more than
70% in the 1990s [3,4].
The rarity of this disease means that most information
regarding survival is derived from these clinical trials.
However, overall survival (OS) results differ between
clinical trials and population-based cancer registries be-
cause of important differences between patients treated
in routine practice and those treated in clinical trials.
For example, IRSG reports showed a 5-year OS of 70%
in the 1990s [3,4], while, even in the 2000s, the 5-year
OS was only approximately 50% in children with RMS
according to population-based data [5]. Clinical trials
may select participants based on strict inclusion criteria,
which consider the extent of disease, previous history of
treatment, comorbidities, psychosocial conditions andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow chart for the creation of the Surveillance,
Epidemiology, and End Results (SEER) data set.
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be excluded from the protocol. OS in trials may there-
fore not reflect the prognosis of patients who receive
treatment in a community setting.
Individualized estimation of the prognosis could be use-
ful for counseling cancer patients on treatment selection
and for optimizing therapeutic approaches [7]. However,
to the best of our knowledge, there is currently no such
estimation tool for RMS based on patients from the gen-
eral population. In this study, we analyzed the OS in chil-
dren and adolescents with RMS using population-based
data collected by the Surveillance, Epidemiology, and End
Results (SEER) program of the National Cancer Institute
(NCI) [5], and constructed a nomogram based on vari-
ables collected from the routine cancer registry, with the
aim of providing clinicians and patients with a practical
clinical tool to predict survival.
Methods
Study population
The data were derived from the SEER program, which
collects demographic, diagnostic and treatment informa-
tion on all newly diagnosed cancer patients residing
within specific US geographic regions. Registry data are
submitted without personal identifiers to the NCI, and
these data are publicly available for research purpose.
Because all information in public-use SEER database re-
mains de-identified, approval by an ethics committee
was not necessary to perform the analysis [8]. All au-
thors have signed the data-use agreement and got per-
mission from SEER program to use this data.
Using the SEER registry public database, we identified
patients with RMS diagnosed from 1990 to 2010 [5].
Children diagnosed with malignant, first primary RMS
and aged 0–19 years were eligible for this analysis. In
this study, eligible RMS cases had International Classifi-
cation of Childhood Cancer (ICCC) code IXa, corre-
sponding to ICO-O-3 morphology codes: 1) RMS not
otherwise specified 8900/3; 2) pleomorphic RMS adult-
type 8901/3; 3) mixed-type RMS 8902/3; 4) embryonal
RMS 8910/3; 5) spindle cell RMS 8912/3; 6) alveolar
RMS 8920/3; or 7) embryonal sarcoma 8991/3. Patients
were excluded from the analysis if the diagnosis was
made at autopsy or by death certificate only. Patients
with no confirmation of diagnosis by microscopy were
also excluded. After selection, there were 1679 cases left
in the cohort. The flow chart for data selection is shown
in Figure 1.
Data analysis
In the description of variables and calculation of OS, age
at diagnosis was classified as 0–4, 5–9, 10–14 or 15–19
years. Age at diagnosis was treated as a continuous vari-
able in multivariate analysis. Other clinical factorsincluded primary tumor site, histologic tumor subtype,
tumor stage, tumor size, surgery and radiotherapy (RT).
Primary tumor sites were classified as favorable or un-
favorable based on the criteria for staging of pediatric
tumors [9]. The head and neck (nonparameningeal),
genitourinary (non-bladder/prostate), and bile duct re-
gions were defined as favorable sites, all other sites were
defined as unfavorable, and an unknown site was regarded
as a missing value. Histology was classified as embryonal,
alveolar or other histological subtype. Histological sub-
types with RMS not otherwise specified were treated as
missing values. Tumor stage was classified according to
the SEER historic staging system. Cases with insufficient
information to define the stage were regarded as having a
missing value. Tumor size was truncated at 20 cm and
was grouped into three levels for both character descrip-
tion and calculation of OS: 1) 0–4 cm; 2) 5–9 cm; and
3) ≥10 cm. Size was treated as a continuous variable in the
multivariate model.
Statistical methods
All missing values were imputed with the ‘transcan’
function of the rms package [10]. OS was calculated by
the Kaplan-Meier product-limited method. Survival
curves were compared using the log-rank test. Cox pro-
portional hazard regressions were performed to assess
the effects of covariates on OS. For continuous variables,
we fitted restricted cubic splines with three knots at
10%, 50% and 90% empirical quantiles. We also consid-
ered the interaction effect between surgery and RT. The
proportional hazard assumption was justified by examin-
ing residual plots. The Akaike information criterion was
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gram with the beta coefficients of variables in the re-
duced model.
The model was internally validated. We generated 200
bootstrap samples to determine the calibration and dis-
crimination of the model. Calibration refers to the ability
of a model to make unbiased estimates of outcome. Cali-
bration was assessed using a calibration curve generated
by plotting the model-predicted 5-year and 10-year sur-
vival probabilities against the observed probability, as
calculated by the Kaplan-Meier method. The prognostic
accuracy of the model was quantified by computing the
concordance index (c-index) described by Harrell et al.
[11]. The c-index is a discrimination measure that esti-
mates the probability that, of two randomly chosen pa-
tients, the patient with the higher predicted survival will
outlive the patient with the lower predicted survival.
The c-index ranges from 0.5 (no discrimination) to 1.0
(perfect discrimination).
All statistical analyses were conducted using R version
3.1.0 software (Institute for Statistics and Mathematics,
Vienna, Austria; www.r-project.org) [12]. The model and
nomogram were constructed using the R package rms
[10]. All statistical tests were two-sided, and values of p
< 0.05 were considered significant.
Results
Patient demographics are listed in Table 1. A total of
1679 pediatric patients with RMS were included in the
study. Approximately 38.1% of the subjects were aged
0–4 years, 23.2% were 5–9 years, 20.6% were 10–14
years and 18.1% were 15–19 years. There were 974
(58.0%) boys, and 705 (42.0%) girls. The majority of pa-
tients were white (75.9%). Approximately 61.1% of RMS
occurred at unfavorable sites. Around 59.0% of patients
were diagnosed with embryonal RMS, 33.2% with alveo-
lar RMS and 7.7% with other RMS. Based on SEER sta-
ging, 33.4% of patients had localized tumors, 34.9% had
regional RMS and 31.7% had metastasis. More than half
(62.8%) of the patients had received RT, and 59.1% re-
ceived surgery.
The 5-year OS rate for the entire cohort was 64.5%
(95% confidence interval (CI), 62.1-67.1%) and the 10-
year OS rate was 61.8% (95%CI, 59.2-64.5%). Five- and
10-year OS rates by characteristic are listed in Table 1.
Sex and race had no influence on OS. Prognosis wors-
ened with increasing age; young children (0–4 years)
had a better prognosis than adolescents (15–19 years),
with 5-year OS of 71.3% and 47.9%, respectively. Chil-
dren with embryonal RMS had a longer survival than
those with alveolar RMS, with estimated 5-year OS of
73.5% and 46.3%, respectively. Patients with localized tu-
mors had a better prognosis (5-year OS of 84.0%) than
those with regional disease (72.4%) or distant metastasis(35.7%). RMS at favorable sites had a better prognosis
than that at unfavorable sites (p < 0.001). Patients with
surgery had improved survival compared with those
without surgery (p < 0.001). RT showed a weak but sig-
nificant association with prognosis; 5-year OS was 65.6%
in patients with RT compared with 62.7% in those with-
out RT (p = 0.045).
Multivariate analysis was performed using a Cox pro-
portional hazards regression model. We pre-specified
nonlinearity for age at diagnosis and tumor size vari-
ables, and considered the effect on prognosis of the
interaction between surgery and RT. Residual plots indi-
cated that the proportional hazards assumption held.
After model selection, we obtained a reduced model.
Beta coefficients and hazard ratios of variables are listed
in Table 2.
The nomogram included age at diagnosis, size, tumor
site, stage, histological type, surgery and RT (Figure 2).
To use the nomogram, we drew a vertical line to the
point row to assign point values for each variable,
summed the point values for each variable to obtain
total points, and then dropped a vertical line from the
total points row to get the 5- and 10-year OS rates.
The model was internally validated. Discrimination
suggested good accuracy with a bootstrap-corrected c-
index of 0.74, which denotes 74% probability that, of two
randomly selected patients, the patient who survives lon-
ger will have a higher survival probability than the pa-
tient with shorter survival. The calibration plots for 5-
and 10-year OS are shown in Figure 3. Points in the cali-
bration plot were close to the 45° line, which suggested
that the model was well-calibrated for all predictions.
Discussion
The current study evaluated OS among pediatric pa-
tients with newly-diagnosed RMS in a population-based
dataset, and constructed a nomogram to predict 5- and
10-year OS. This prognostic tool will be useful for esti-
mating prognosis and guiding treatment selection.
The rarity of this disease means that most published
studies are retrospective analyses of clinical studies, or
small, single-institution, observational studies. Results
from a single institution often fail to identify a true rela-
tionship between outcome and risk factors because of
the small sample size and short follow-up period. Our
analyses were based on the SEER database, which is con-
sidered to be the largest cancer registry. Reports from a
population-based cohort have the advantage of including
many more patients, thus increasing the power to esti-
mate the true effects of risk factors on survival. More-
over, unlike most results from clinical studies, analysis of
a population-based database includes not only those
treated using formal protocols, but also those excluded
from protocols because of comorbidity, tumor stage, or
Table 1 Patient demographics and overall survival
All patients 5 Years OS (%) 10 Years OS (%) p
Characteristics No. Events Rate 95%CI Rate 95%CI
Entire cohort 1679 543 64.5 62.1-67.1 61.8 59.2-64.5
Age (years) <0.001
0-4 639 173 71.3 67.5-75.2 69.1 65.2-73.2
5-9 390 97 73.2 68.5-78.2 68.8 63.6-74.5
10-14 346 134 56.4 50.9-62.6 52.4 46.6-59.0
15-19 304 139 47.9 42.1-54.6 47.3 41.5-54.0
Tumor size (cm) <0.001
0-4 618 116 79.5 76.0-83.1 77.1 73.4-81.1
5-9 675 237 61.6 57.7-65.7 57.6 53.5-62.1
≥10 386 190 45.9 40.7-51.7 44.4 39.1-50.3
Sex 0.311
Male 974 306 65.7 62.5-69.1 62.5 59.1-66.1
Female 705 237 63.0 59.2-67.0 60.8 56.8-65.0
Race 0.359
White 1274 407 65.2 62.4-68.1 62.2 59.2-65.3
Black 277 88 64.0 58.0-70.7 62.2 55.9-69.2
Others 128 48 58.7 50.0-69.0 56.6 47.5-67.5
Site <0.001
Unfavorable 1026 406 56.6 53.2-59.9 53.5 50.1-57.1
Favorable 653 137 77.1 73.6-80.7 74.6 70.8-78.5
Stage <0.001
Localized 561 83 84.0 80.7-87.5 81.1 77.3-85.1
Regional 586 152 72.4 68.6-76.5 68.5 64.3-73.1
Distant 532 308 35.7 31.5-40.5 34.4 30.1-39.2
Histology <0.001
Embryonal 991 249 73.5 70.6-76.5 70.8 67.6-74.1
Alveolar 558 263 46.3 41.9-51.2 43.2 38.7-48.3
Others 130 31 73.1 64.9-82.3 71.4 62.9-81.0
Surgery <0.001
None 686 294 52.0 48.0-56.2 50.4 46.4-54.7
Surgery 993 249 73.2 70.2-76.3 69.9 66.3-73.0
Radiotherapy 0.045
None 625 213 62.7 58.7-67.0 60.8 56.6-65.3
Radiation 1054 330 65.6 62.5-68.9 62.3 59.1-65.8
OS, overall survival; CI, confidence interval.
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spectrum of the disease. Furthermore, SEER data are
high quality and are collected in a uniform manner with
uniform data standards. Quality control ensures that the
SEER program has a relatively low rate of errors in the
cancer registry [6].
Our study cohort included 1679 RMS patients and 543
deaths, which sample size was adequate to establish areasonable model. The outcome measure of OS is one
of the most useful pieces of information for counseling
and is commonly used to develop staging schemes. Al-
though the nomogram is not perfectly accurate, the
error bars in the calibration plot suggest that predictions
from the nomogram are within approximately 5% of
the actual probability on average, and the bootstrap-
corrected c-index of 0.74 suggests that the nomogram
Table 2 Cox proportional hazards multivariate regression
model parameters
Covariate Beta coefficient Hazard ratio 95% CI p
Age −0.037* -** - 0.154
Age’ 0.089* -** - 0.013
Size 0.006† -†† - 0.095
Size’ −0.004† -†† - 0.359
Favorable site −0.204 0.82 0.65-1.02 0.076
Stage
Regional 0.404 1.50 1.13-1.98 0.004
Distant 1.259 3.52 2.64-4.70 <0.001
Histology
Alveolar 0.497 1.64 1.35-2.00 <0.001
Other −0.135 0.87 0.59-1.29 0.499
Received surgery −0.612 0.54 0.40-0.72 <0.001
Received RT −0.632 0.53 0.42-0.68 <0.001
Interaction terms
Surgery × RT 0.564 1.75 1.24-2.50 0.002
CI, confidence interval; RT, radiotherapy.
*Age was modeled using a restricted cubic spline function with three knots,
which yields two independent beta coefficients, annotated as Age and Age’.
**The hazard ratio varies continuously with age.
†Size was modeled using a restricted cubic spline function with three knots,
which yields two independent beta coefficients, annotated as Size and Size’.
††The hazard ratio varies continuously with size.
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curacy is comparable with most published nomograms
for cancer prognosis.
The prognostic nomogram is a model-based tool to pre-
dict patient outcome. It directly quantifies the prognosis
of individual patients based on proven prognostic factors.
Different from a staging or scoring system, a nomogram
considers multiple commonly available prognostic vari-
ables simultaneously, including continuous variables. Indi-
vidual predictions are expressed on a probability scale,
making it more easily understood by patients and clini-
cians than relative rates or hazard ratios [13]. A nomo-
gram has the potential to stratify patients for clinical
studies, meaning that treatment regimens can be tested in
more homogenous populations. Selecting high-risk pa-
tients based on predictions from a nomogram can also
help to improve trial efficiency; for example, trials evaluat-
ing a treatment strategy could target patients with poor
prognoses. Identifying high-risk patients for trial recruit-
ment using a nomogram will increase the power to detect
differences among treatment effects, thus reducing the re-
quired sample size. This method has been used in pro-
spective randomized trials [14].
There is increasing interest in personalized medicine.
A number of cancer nomograms to predict prognosis
have been published in recent decades, such as forprostate, breast, soft-tissue sarcoma, and other cancers,
including our previous nomogram for thyroid cancer
[7,15-23]. To the best of our knowledge however, the
nomogram constructed in this study represents the first
OS nomogram for pediatric RMS that is generalizable to
the population.
The results of the Cox model identified age at diagno-
sis, stage of tumor, tumor size, histological subtype and
treatment as important predictors of RMS survival in
pediatric patients. The findings are expressed consist-
ently in the nomogram. For example, adolescence, dis-
tant disease, large tumor size, alveolar RMS and no
treatment, which were associated with a reduced survival
based on the model, were given larger points in the
nomogram. Meanwhile, a larger total point indicates a
lower OS.
Simplicity is a strength of our model. Unlike models
that aim to identify associations between prognosis and
risk factors, predictive models should focus more on ac-
curacy and parsimony [24]. Complex models including a
number of variables may be abandoned in clinical prac-
tice. In contrast, the nomogram developed in this study
relies on limited variables that are routinely available
from the tumor registry, making it easy for clinicians to
use to calculate survival for individual patients.
Adult RMS was not included in this model. Pediatric
and adult RMS have different clinical characteristics and
prognoses. For example, pleomorphic RMS is common
among adult patients, but is seldom seen in pediatric pa-
tients. Additionally, adult patients have a poorer re-
sponse to chemotherapy. Research has suggested that
increased levels of a resistance-related protein in adult
embryonal and pleomorphic RMS compared with
pediatric RMS may explain the reduced response to
chemotherapy [25]. Information regarding chemotherapy
and variables in the protein level was not available in the
current study and it was therefore not possible to adjust
for these potential effects on prognosis in the SEER co-
hort. Moreover, adult RMS may have lower pathologic
accuracy compared with pediatric RMS [9]. We there-
fore excluded adult RMS from the current analysis to
avoid these confounders and bias and to increase the ac-
curacy of the model.
Although our nomogram showed reasonable accuracy
for predicting OS, care should be taken when using a
nomogram for counseling. Because it is impossible to in-
clude all risk factors, the prognostic predictive value of a
nomogram should not be used as the sole basis for
selecting a treatment regimen; treatment should be se-
lected based on not only the expected value from the
nomogram, but also taking into account other prognos-
tic factors and quality of life.
There were some limitations to our study. First, the
SEER public dataset does not include information on
Figure 2 Nomogram for predicting 5- and 10-year overall survival and median survival time. Instructions: Locate the patient’s characteristic on
the variable row, draw a vertical line straight upward to the points row to obtain a points value for the variable. Move to the next row of
variables, and repeat this process to get points for each variable. Sum the total points and drop a vertical line from the total points row to
assign the values for overall survival rates.
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are viewed as important prognostic variables. This infor-
mation would be useful for refining the predictive model.
Second, although we restricted our cohort to patients
diagnosed after 1990, the study period still spanned
approximately two decades, during which time there have
been improvements in surgery, chemotherapy and RT.
Our nomogram thus tends to underestimate current OS.
Third, unlike IRSG clinical trials, the SEER program doesFigure 3 Calibration plot. (A) Five-year overall survival; (B) 10-year overal
between predicted and observed survivals. Vertical arrows represent 95% c
predictive accuracy. X marks the bootstrap-corrected estimates.not utilize a central pathology review to minimize mis-
classification [6]. Finally, we used internal validation to
evaluate the accuracy of the model, and external validation
based on independent data would be useful to validate the
model further.
Conclusions
In conclusion, we used a population-based dataset to es-
tablish and internally validate a model to estimate thel survival. The grey line is the “ideal” line if there is a perfect match
onfidence intervals of observed survival. Dots correspond to apparent
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10 years after being diagnosed with RMS. This study
represents an objective analysis of all currently available
data from the SEER cancer registry. The model shows
good ability to discriminate among patients, with a
c-index of 0.74. This predictive tool may be useful for
patient counseling and to enable more individualized
treatment planning.
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